Lantheus Holdings, Inc.

LNTH Healthcare Drug Manufacturers Specialty & Generic

Lantheus Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 0.50% from fiscal 2024. In the quarter to June 2026, revenue grew 2.68%, EPS was flat, free cash flow grew 13.6% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.

99.70 0.29 −0.29%
Market cap
$6.5B
P/E
23.7×
Fwd P/E
25.3×
Dividend yield
—
F-score
5/9
Altman Z
4.25
Beneish M
−2.23
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

5 5 5 5
ROE
14.59% 21.45% 23.48% 22.21%
ROA
7.75% 11.10% 12.68% 12.15%
ROIC
16.63% 14.94% 14.12% 14.65%
Return on Tangible Assets
22.59% 31.98% 36.39% 32.59%
Average Days of Receivables
91.67 88.56 84.31 83.04
Free Cash Flow per Share
6.30 5.25 5.90 6.03
Free Cash Flow
423.79 354.05 382.11 392.83
Capital Expenditures
(33.90) (36.09) (25.60) (19.97)
Other line items
Cash ROIC
20.47% 17.54% 16.75% 15.86%
Accounts Receivable Turnover
4.28 4.38 4.38 4.51
Accounts Payable Turnover
10.36 15.48 13.47 13.94
Inventory Turnover
8.67 9.04 9.37 10.36
Average Days of Payables
41.99 26.12 27.40 28.31
Days of Inventory on Hand
39.29 39.37 36.64 33.86
Tax Rate
(0.31) (0.26) (0.25) (0.24)
Research and Development Expense of Revenue
10.82% 11.50% 11.67% 11.12%
Selling, General and Administrative Expense of Revenue
28.78% 29.44% 30.06% 29.60%
Share Based Compensation of Revenue
5.91% 5.55% 5.20% 5.02%
Interest Coverage
17.63 15.74 14.64 15.26
Operating CF/Net income
2.73 1.67 1.46 1.50
Depreciation/Fixed assets
0.42 0.46 0.53 0.61
Capex/Depreciation
(0.49) (0.48) (0.31) (0.21)
Revenue per Share
22.70 22.84 23.88 23.88
Operating CF per Share
6.81 5.78 6.30 6.34
Capex per Share
(0.50) (0.53) (0.40) (0.31)
Capex to Sales
0.02 0.02 0.02 0.01

Fold the line items

Columns are period end dates